Exp Clin Endocrinol Diabetes 2008; 116(9): 537-540
DOI: 10.1055/s-2008-1058087
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

The Effects of Rosiglitazione on Renal Artery Endothelium in Diabetic Rats

Y. L. Lu 1 , Y. M. Jimbu 2 , Y. Chen 1 , J. B. Zhao 1 , T. T. Ye 1 , H. Yang 1
  • 1Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital Affiliated Shanghai Jiaotong University School of Medicine, Shanghai, China
  • 2Department of Neurology, Hematology, Metabolism, Endocrinology and Diabetology, Yamagata University School of Medicine, Yamagata, Japan
Further Information

Publication History

received 15.10.2007 first decision 27.11.2007

accepted 11.02.2008

Publication Date:
17 March 2008 (online)

Zoom Image

Abstract

Backround: Macrovascular disease is a common complication of Diabetes Mellitus (DM). Study of renal artery endothelium may serve as a surrogate for cardiovascular and renal vascular disease.

Object: This study is to elucidate (1) how about the changes of renal endothelial ultrastructures it is in different time of diabetes animals? (2) Whether PPARgamma ligand (such as rosiglitazone: ROS) could improve endothelium destruction in diabetes?

Methods: Streptozoticin (STZ) induced diabetic rats were stratified by age groups from 6 to 10 weeks of age and were paired with age-matched control non-diabetic rats. Further, another group of diabetic rats were treated with ROS and matched with non-treated diabetic rats.

Result: The renal artery endothelium of diabetic rats was partially coarse, distended, cracked and destroyed. The Vascular Endothelial Structure Score (VESS) was 34.5 in diabetic rats compared with non-diabetic control male rats (P=0.001). The older rats demonstrated more endothelial wall damage, more pronounced in male rats. Compared with non-treated control diabetic rats, ROS prevented diabetic endothelial damage (VESS=4.6, P=0.001).

Conclusion: Renal artery endothelium damage in STZ induced diabetic rats was significantly attenuated by rosiglitazone.